Compare2 records
2 records on the same 7 fields; 6 differ.
A rust rule marks a value that differs from most of the others. Fields carry their source quote where one exists.
| Field | NCT04381130↗ A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer | NCT07608627↗ 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced … |
|---|---|---|
| Phasediffers | Phase 1 / Phase 2 | Phase 1 |
| Status | Not yet recruiting | Not yet recruiting |
| Enrollmentdiffers | 30 | 15 |
| Startdiffers | 1 April 2027 | 16 December 2026 |
| Sponsor classdiffers | Industry | Other |
| Interventiondiffers | Drug: EF-009Drug: EF-009. Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of med… | Procedure: Biospecimen Collection; Drug: Copper Cu 64-DOTA-A2DM; Procedure: Positron Emission Tomography; Other: RadioconjugateProcedure: Biospecimen Collection. Undergo blood sample collection |
| Primary endpointdiffers | Maximum Tolerated Dose (MTD)Maximum Tolerated Dose (MTD). Phase I Time frame: 21 days. | Incidence of adverse eventsIncidence of adverse events. Graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 6.0. Time frame: Up to 90… |
Why might these disagree?
- Phase. They are at different phases, so they answer different questions (safety and dose versus efficacy).
- Enrollment. Their sizes differ, which changes how precise any result can be.
- Start. They ran at different times, against different standards of care.
- Sponsor class. Industry and academic sponsors often select patients and endpoints differently.
- Intervention. They test different drugs or combinations.
- Primary endpoint. They measure success differently, so their results are not directly comparable.